Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity

Journal of Biological Chemistry ◽

10.1074/jbc.ra119.007758 ◽

2019 ◽

Vol 294 (48) ◽

pp. 18337-18348 ◽

Author(s):

Jayshree Mishra ◽

Randall Simonsen ◽

Narendra Kumar

Keyword(s):

Breast Cancer ◽

Breast Cancer Resistance Protein ◽

Janus Kinase ◽

Drug Efflux ◽

Cancer Resistance ◽

Barrier Functions ◽

Resistance Protein ◽

Download Full-text

The effects of human immunodeficiency virus infection on the expression of the drug efflux proteins P-glycoprotein and breast cancer resistance protein in a human intestine model

Journal of Pharmacy and Pharmacology ◽

10.1111/jphp.12329 ◽

2014 ◽

Vol 67 (2) ◽

pp. 178-188 ◽

Author(s):

Kelstan Ellis ◽

Jerry W. Marlin ◽

Tracey A.H. Taylor ◽

Sylvia Fitting ◽

Kurt F. Hauser ◽

...

Keyword(s):

Breast Cancer ◽

Human Immunodeficiency Virus ◽

Virus Infection ◽

Breast Cancer Resistance Protein ◽

Drug Efflux ◽

Human Intestine ◽

Cancer Resistance ◽

P Glycoprotein ◽

Immunodeficiency Virus ◽

Resistance Protein

Download Full-text

Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization

International Journal of Cancer ◽

10.1002/ijc.10100 ◽

2002 ◽

Vol 97 (5) ◽

pp. 626-630 ◽

Author(s):

Kumie Kage ◽

Satomi Tsukahara ◽

Tomomi Sugiyama ◽

Sakiyo Asada ◽

Etsuko Ishikawa ◽

...

Keyword(s):

Breast Cancer ◽

Breast Cancer Resistance Protein ◽

Efflux Pump ◽

Dominant Negative ◽

Drug Efflux ◽

Cancer Resistance ◽

Resistance Protein ◽

Drug Efflux Pump

Download Full-text

Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Molecular Cancer Therapeutics ◽

10.1158/1535-7163.mct-10-0438 ◽

2011 ◽

Vol 10 (1) ◽

pp. 117-125 ◽

Author(s):

Xiaonan Hou ◽

Fei Huang ◽

Joan M. Carboni ◽

Karen Flatten ◽

Yan W. Asmann ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Insulin Receptor ◽

Breast Cancer Resistance Protein ◽

Growth Factor Receptor ◽

Drug Efflux ◽

Cancer Resistance ◽

Mechanism Of Resistance ◽

Resistance Protein ◽

Receptor Inhibitor

Download Full-text

Identification of molecular switch regulating tyrosine phosphorylation of Intestinal breast cancer resistance protein (BCRP) mediated mucosal wound repair and barrier functions in obesity

The FASEB Journal ◽

10.1096/fasebj.2021.35.s1.03566 ◽

2021 ◽

Vol 35 (S1) ◽

Author(s):

Jayshree Mishra ◽

Narendra Kumar

Keyword(s):

Breast Cancer ◽

Tyrosine Phosphorylation ◽

Breast Cancer Resistance Protein ◽

Wound Repair ◽

Molecular Switch ◽

Cancer Resistance ◽

Barrier Functions ◽

Resistance Protein ◽

Download Full-text

Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.

10.1158/0008-5472.sabcs-2149 ◽

2009 ◽

Author(s):

P Haluska ◽

JM Carboni ◽

YW Asmann ◽

C Ten Eyck ◽

RM Attar ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor ◽

Insulin Receptor ◽

Breast Cancer Resistance Protein ◽

Growth Factor Receptor ◽

Drug Efflux ◽

Cancer Resistance ◽

Mechanism Of Resistance ◽

Resistance Protein ◽

Receptor Inhibitor

Download Full-text

The Gut Microbiota Ellagic Acid-Derived Metabolite Urolithin A and Its Sulfate Conjugate Are Substrates for the Drug Efflux Transporter Breast Cancer Resistance Protein (ABCG2/BCRP)

Journal of Agricultural and Food Chemistry ◽

10.1021/jf4007505 ◽

2013 ◽

Vol 61 (18) ◽

pp. 4352-4359 ◽

Author(s):

Antonio González-Sarrías ◽

Verónica Miguel ◽

Gracia Merino ◽

Ricardo Lucas ◽

Juan C. Morales ◽

...

Keyword(s):

Breast Cancer ◽

Gut Microbiota ◽

Ellagic Acid ◽

Breast Cancer Resistance Protein ◽

Drug Efflux ◽

Efflux Transporter ◽

Cancer Resistance ◽

Urolithin A ◽

Resistance Protein ◽

Sulfate Conjugate

Download Full-text

Faculty Opinions recommendation of The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13353972.14725070 ◽

2011 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Proximal Tubule ◽

Breast Cancer Resistance Protein ◽

Apical Membrane ◽

Human Kidney ◽

Cancer Resistance ◽

Kidney Proximal Tubule ◽

Resistance Protein

Download Full-text

Faculty Opinions recommendation of Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.3171959.2859057 ◽

2010 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Breast Cancer Resistance Protein ◽

Cancer Resistance ◽

Active Efflux ◽

P Glycoprotein ◽

Resistance Protein ◽

Download Full-text

Faculty Opinions recommendation of Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725783242.793517907 ◽

2016 ◽

Author(s):

Susan Bates

Keyword(s):

Breast Cancer ◽

Breast Cancer Resistance Protein ◽

Cancer Resistance ◽

Glycoprotein P ◽

Alk Inhibitor ◽

P Glycoprotein ◽

Resistance Protein

Download Full-text

Faculty of 1000 evaluation for The "specific" P-glycoprotein inhibitor tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.9419956.10057054 ◽

2011 ◽

Author(s):

Robert Fecik

Keyword(s):

Breast Cancer ◽

Breast Cancer Resistance Protein ◽

Cancer Resistance ◽

P Glycoprotein ◽

Resistance Protein

Download Full-text